Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Methods:</b> A systematic search in electronic databases was performed to identify studies on selective estrogen receptor modulators (SERM) and down-regulators (SERD) and aromatase inhibitors that reported on response rates (RR) among EC patients.
|
31134155 |
2019 |
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The primary aim of our study was to investigate the incidence of endometrial pathologies, especially endometrial cancer, in women with breast cancer treated with tamoxifen (TAM), aromatase inhibitors (AIs), or receiving no treatment (NT).
|
31425735 |
2019 |
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
In placebo-controlled trials, tamoxifen increased endometrial cancer (RR 2.25; 95% CI, 1.17 to 4.41; 3 trials), while raloxifene and aromatase inhibitors did not.
|
31509915 |
2019 |
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
The clinical benefit rate with aromatase inhibitors and the impact of treatment on quality of life (QOL) in endometrial cancer is unclear.
|
31130288 |
2019 |
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer.
|
31074242 |
2019 |
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Based on long-term adverse effects and complication safety data, when compared with tamoxifen, aromatase inhibitors are associated with a reduced incidence of thrombosis, endometrial cancer, and vaginal bleeding.
|
29794680 |
2018 |
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, positive correlation between CYP19A1 and LPAR1 accounts for supporting role of LPA acting via LPAR1 in intratumoral DHT concentration and the ethiology of endometrial cancer progression.
|
29182028 |
2018 |
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Based on long-term adverse effects and complication safety data, when compared with tamoxifen, aromatase inhibitors are associated with a reduced incidence of thrombosis, endometrial cancer, and vaginal bleeding.
|
29794673 |
2018 |
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Contradictory results are reported about the level of steroid sulfatase (STS), estrogen sulfotransferase (SULT1E1; together, the sulfatase pathway) and aromatase (CYP19A1) in endometrial cancer (EC).
|
30217785 |
2018 |
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
The emergence of intracrinology, associated with disordered expression of key enzymes such as aromatase, in the aetiology of common women's health disorders such as endometriosis and endometrial cancer has prompted renewed interest in the development of drugs targeting these pathways, opening up new opportunities for targeted therapies and precision medicine.
|
30360364 |
2018 |
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Preliminary clinical application of an aromatase inhibitor and a gonadotropin-releasing hormone agonist combination for inoperable endometrial cancer patients with comorbidities: case report and literature review.
|
29584567 |
2018 |
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aromatase inhibitor (AI) drugs are used in the treatment of both diseases, however, response rates for AIs are low and there is currently no way to identify breast or endometrial cancer patients who are more likely to receive a clinical benefit.
|
28487654 |
2017 |
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We analyzed 2937 single nucleotide polymorphisms (SNPs) in 6608 endometrial cancer cases and 37 925 controls and report the first genome wide-significant association between endometrial cancer and a CYP19A1 SNP (rs727479 in intron 2, P=4.8×10(-11)).
|
26574572 |
2016 |
Malignant neoplasm of endometrium
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Aromatase expression and regulation in breast and endometrial cancer.
|
27067638 |
2016 |
Malignant neoplasm of endometrium
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Altered expression of ERs, aromatase, and COX2 connected to estrogen action in type 1 endometrial cancer biology.
|
23873111 |
2013 |
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Adjusting for endometrial cancer risk factors, the A allele of rs4775936 in CYP19 was significantly associated (OR(per allele)=1.22, 95% CI=1.01-1.47, p(trend)=0.04), while the T allele of rs10046 was marginally associated with increased risk of endometrial cancer (OR(per allele)=1.20, 95% CI=0.99-1.45, p(trend)=0.06).
|
22633539 |
2012 |
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We found no significant association between CYP19A1 genotypes and haplotypes and endometrial cancer risk.
|
22320986 |
2011 |
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, we identified regions in AR and CYP19A1 that are of interest for further evaluation in relation to endometrial cancer risk in future haplotype and subsequent fine mapping studies in larger study populations.
|
20053928 |
2010 |
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium.
|
19124504 |
2009 |
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that GFP expression is driven by estrogen synthesized by aromatase in the endometrial cancer stromal cells.
|
18508998 |
2008 |
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The insertion/deletion variant in CYP19A1 appears to be related to risk of endometrial cancer; risk associated with variants in this gene may vary according to BMI.
|
18437511 |
2008 |
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, increased risk of endometrial cancer with long-term tamoxifen administration and of bone fracture due to osteoporosis in postmenopausal women undergoing aromatase inhibitor therapy are recognized side effects.
|
17280616 |
2007 |
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Linked variants in CYP19A1 (intron 4 [TTTA]n, intron 4 [TCT] insertion/deletion, exon 10 C/T) are related to some hormone levels and, based on two studies, to risk of endometrial cancer.
|
17110639 |
2007 |
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our result, although needs further investigation on the cause of the difference from other studies, suggested that aromatase might not have an important role in endometrial cancer.
|
17404019 |
2007 |
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The authors' findings suggest that tea polyphenols may modify the effect of CYP19A1 genetic polymorphisms on the development of endometrial cancer.
|
17827443 |
2007 |